Trusted Resources: Education
Scientific literature and patient education texts
Hereditary ATTR Amyloidosis: Burden of Illness and Diagnostic Challenges
source: The American Journal of Managed Care
year: 2017
authors: Gertz MA
summary/abstract:Hereditary transthyretin-mediated (hATTR) amyloidosis is a progressive disease characterized by deposition of amyloid fibrils in various organs and tissues of the body. There are a wide variety of clinical presentations for this multisystemic disorder, so it is often misdiagnosed or subject to delayed diagnosis. Although the exact prevalence is difficult to determine, existing estimates suggest a worldwide prevalence of 50,000 individuals, with varying phenotypic presentations of disease. Due to the heterogeneous nature of its presentation, incorrect or delayed diagnosis can severely impact quality of life for these patients. hATTR amyloidosis can lead to significant disability and mortality.
After an accurate diagnosis of hATTR amyloidosis is established, new patients should undergo appropriate therapy as soon as possible. Current treatment options for hATTR amyloidosis are limited, but orthotopic liver transplant serves as an established option for patients with early-stage disease. Consequently, there is a need for new, effective, and safe therapies.
organization: Mayo Clinic, USAread more full text
Related Content
-
Gregory Foster AL Amyloidosis “A Fight for Answers”https://www.youtube.com/watch?v=HkKTyKBr...
-
Choosing Not to Continue Your Career After hATTR Amyloidosis DiagnosisDeciding to leave your job following you...
-
Cerebral Amyloid Angiopathy Mimicking Central Nervous System Metastases: A Case ReportBackground: This case describes an unus...
-
Cardiac Amyloidosis Diagnostic Workuphttps://www.youtube.com/watch?v=gaWfWCph...
-
Inotersen: An Exciting Prospect for hATTR Amyloidosis TreatmentA new hereditary ATTR (hATTR) amyloidosi...
-
Evolving Landscape in the Management of Transthyretin AmyloidosisTransthyretin (TTR) amyloidosis (ATTR am...
-
Atrophic Nodular Cutaneous AmyloidosisPrimary cutaneous amyloidosis is limited...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.